Baxter International Under Investigation for Alleged Malfunctions of Novum LVP Infusion Pumps
- Baxter International is under investigation for misrepresenting the safety of its Novum LVP infusion pumps linked to patient malfunctions.
- Allegations suggest Baxter's executives neglected known device issues, risking patient health and the company's reputation.
- Investors must act by December 15, 2025, to join potential class action lawsuits against Baxter over these claims.
Baxter International Faces Legal Scrutiny Over Alleged Device Malfunctions
Baxter International Inc. is currently under investigation by multiple law firms for potential legal claims linked to significant investor losses related to its Novum LVP infusion pumps. The allegations stem from claims that between February 23, 2022, and July 30, 2025, Baxter misrepresented the safety and functionality of these medical devices, which reportedly have systemic defects. Malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids have raised grave concerns over patient safety, casting a shadow over the company's credibility and operational integrity. The situation has prompted law firms like Faruqi & Faruqi, LLP and the Law Offices of Frank R. Cruz to reach out to affected investors, urging them to consider their legal options.
The complaints allege that Baxter's executives were aware of multiple incidents involving device malfunctions, injuries, and fatalities but failed to take appropriate remedial actions. This negligence not only jeopardizes patient health but also poses a substantial risk to Baxter's reputation and market position. As customers become increasingly aware of these issues, the likelihood of existing Novum LVPs being withdrawn from service rises, along with the potential halt of new sales. Given the severity of these allegations, Baxter's public statements regarding the safety, efficacy, and market prospects of the Novum LVPs are deemed materially misleading, raising significant concerns among investors.
As the legal landscape develops, investors interested in participating in the class action lawsuits must act before the December 15, 2025, deadline to become a lead plaintiff. Firms involved emphasize that participation does not require immediate action other than expressing interest, and investors may select their counsel. This situation highlights the critical importance of transparency and accountability in the medical device industry, where product safety directly impacts patient welfare and investor confidence.
Additionally, the scrutiny from law firms reflects broader concerns within the medical device sector regarding product reliability and corporate governance. As Baxter navigates this turbulent legal environment, the company must take decisive steps to restore trust among its stakeholders. Meanwhile, the legal actions surrounding Baxter serve as a cautionary tale for other firms in the industry to prioritize transparency and address potential defects proactively to avoid similar repercussions.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

